Beekman, S.

Brabander, T.

de Blois, E.

de Ridder, C.

Handula, M.

Konijnenberg, M.

Nonnekens, J.

Ntihabose, C.

Piet, A.

Seimbille, Y.

Stuurman, D.

Tamborino, G.

van Dalen, L.

Zink, J.

English

EUR Research Repository

EUR Research Information PortalComparative studyPublished in:European Journal of Nuclear Medicine and Molecular ImagingPublication status and date:Published: 01/09/2024DOI (link to publisher):10.1007/s00259-024-06838-zDocument VersionPublisher's PDF, also known as Version of recordDocument License/Available under:Article 25fa Dutch Copyright ActCitation for the published version (APA):Ntihabose, C., Handula, M., Beekman, S., Piet, A., van Dalen, L., Zink, J., Stuurman, D., de Ridder, C., Tamborino, G.,Konijnenberg, M., Brabander, T., Nonnekens, J., Seimbille, Y., & de Blois, E. (2024). Comparative study: Exploring theAdvantages of Tb-161 over Lu-177 in Targeted Radionuclide Therapy and the impact of Antagonist vs Agonist. EuropeanJournal of Nuclear Medicine and Molecular Imaging, 51, S830-S830. Article EP-0995. https://doi.org/10.1007/s00259-024-06838-zLink to publication on the EUR Research Information PortalTerms and Conditions of UseExcept as permitted by the applicable copyright law, you may not reproduce or make this material available to any third partywithout the prior written permission from the copyright holder(s). Copyright law allows the following uses of this materialwithout prior permission:            • you may download, save and print a copy of this material for your personal use only;            • you may share the EUR portal link to this material.In case the material is published with an open access license (e.g. a Creative Commons (CC) license), other uses may beallowed. Please check the terms and conditions of the specific license.Take-down policyIf you believe that this material infringes your copyright and/or any other intellectual property rights, you may request itsremoval by contacting us at the following email address: openaccess.library@eur.nl. Please provide us with all the relevantinformation, including the reasons why you believe any of your rights have been infringed. In case of a legitimate complaint,we will make the material inaccessible and/or remove it from the website.EP-63

Comparative study:Exploring the Advantages of Tb-161 over Lu-177 in Targeted Radionuclide Therapy and the impact of Antagonist vs Agonist

https://pure.eur.nl/files/184971085/Comparative_study.pdf

Comparative study:Exploring the Advantages of Tb-161 over Lu-177 in Targeted Radionuclide Therapy and the impact of Antagonist vs Agonist

Abstract

Similar works

Full text

Available Versions

EUR Research Repository

EUR Research Repository